Lercanidipin-Omniapharm Recordati Pharma Gmbh

Lercanidipine hydrochloride, the active ingredient in Lercanidipin-Omniapharm Recordati Pharma Gmbh, is a calcium channel blocker presented as an oral tablet for oral use. It works by relaxing vascular smooth muscle, thereby lowering elevated blood pressure in adult patients with hypertension.

GNH USA supplies Lercanidipin-Omniapharm Recordati Pharma Gmbh as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Lercanidipine is a calcium channel blocker used in the management of hypertension, a condition characterized by elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. Isolated systolic hypertension: provides long‑term blood pressure control in patients with predominant systolic elevation.

Lercanidipine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, typically occurring shortly after dosing. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness: especially when standing quickly. - Tachycardia: increased heart rate in some patients. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

When prescribing or dispensing lercanidipine, several safety considerations should be observed.

Blood pressure monitoring: regularly assess to avoid excessive hypotension. Dose titration: start with a low dose and adjust gradually based on response. Hepatic impairment: use with caution in patients with liver dysfunction. Elderly patients: monitor closely for dizziness and falls. Concomitant CYP3A4 inhibitors: avoid or adjust dose when strong inhibitors are co‑administered. Store at room temperature: keep in the original packaging, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Grapefruit juice: can markedly raise drug levels leading to hypotension. - Other antihypertensives with additive blood‑pressure‑lowering effects: risk of severe hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Diuretics: may enhance orthostatic hypotension; monitor electrolytes. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.